Immunotherapy duo takes on rare sarcoma in new trial
NCT ID NCT04095208
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and relatlimab, can help people with advanced or metastatic soft-tissue sarcoma. The study enrolled 68 adults whose tumors had a specific immune structure. Researchers measured how many patients had their cancer stop growing or shrink over six months. The goal is to find a new way to control this rare cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and relatlimab (immunotherapy drugs)
What this could lead to
If it works, this could offer a new treatment option for people with advanced soft-tissue sarcoma, potentially slowing the disease.
What could go wrong
This is a small, early-phase trial with only 68 participants. The drugs may not work for all sarcoma types, and side effects from immunotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69000, France
-
Hôpital Cochin
Paris, 75014, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut de Cancérologie de l'Ouest - Site René Gauducheau
Nantes, 44805, France